 Home > Biochemistry News > Biotechnology News > FDA approves Keytruda combination therapy as first-line treatment of cervical cancer to reduce the risk of death by 36%

FDA approves Keytruda combination therapy as first-line treatment of cervical cancer to reduce the risk of death by 36%

 Last Update: 2021-12-04
 Source: Internet
 Author: User

Tags

prime plus 1

hypothalamus treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On October 13, 2021, Merck & Co.

The approval is based on the positive results of a pivotal, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial

Compared with chemotherapy, pembrolizumab + chemotherapy reduced the risk of death by 36% (HR=0.

The median PFS of the pembrolizumab+chemotherapy group was 10.

The objective response rates of pembrolizumab+chemotherapy group and chemotherapy group were 68% and 50%, respectively

The median duration of remission in the pembrolizumab+chemotherapy and chemotherapy groups were 18.

Reference materials:

[1] FDA approves pembrolizumab combination for the first-line treatment of cervical cancer.

[2] FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1).

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express FDA today approved Keytruda combination therapy for first-line treatment of cervical cancer, reducing the risk of death by 36%

10-21

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

FDA approves Keytruda combination therapy as first-line treatment of cervical cancer to reduce the risk of death by 36%

Related Articles

Express FDA today approved Keytruda combination therapy for first-line treatment of cervical cancer, reducing the risk of death by 36%